[ET Net News Agency, 16 January 2020] Morgan Stanley raised its target price for Hansoh
Pharmaceutical Group (03692) to HK$30.3 from HK$29 and maintained its "overweight" rating.
The research house said Hansoh has launched three innovative drugs and more than 30
first-to-market generics since 2011, and now it has 100 drugs in its pipeline. In 2019
alone, Hansoh launched two novel drugs. In 2020, Morgan expects Hansoh to launch another
two chemical 1.1 novel drugs and four other likely first-to-market generics into the
Chinese market.
Morgan thinks this pipeline is stronger than most of its peers'. It estimated these
drugs have combined peak sales potential of Rmb17bn+. (KL)